Senate Finance Chair Ron Wyden (D-OR) is pressing the Federal Trade Commission to address a new co-manufacturing practice by pharmacy benefit managers that he says thwarts generic drug competition, warning the commission that the drug chain middlemen are launching new business strategies just as FTC and lawmakers seek to stop PBMs’ traditional tactics. Wyden, in a letter co-signed by Sen. Sherrod Brown (D-OH), applauds FTC for suing the top three PBMs two weeks ago for allegedly inflating insulin prices through...